TITLE

A Review on Novel Formulation Approaches of Azidothymidine

AUTHOR(S)
Nath, Jayalakshmi; Hari, B. N. Vedha; Devi, D. Ramya
PUB. DATE
July 2013
SOURCE
Journal of Pharmaceutical Sciences & Research;2013, Vol. 5 Issue 7, p140
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Azidothymidine (AZT or ZVD), a Nucleoside Reverse Transcriptase Inhibitor (NRTI), is used as antiviral medication to treat Human Immunodeficiency Virus (HIV) which causes Acquired Immunodeficiency Syndrome (AIDS). It is the first approved anti HIV drug for AIDS used either in combination with other antiretroviral agents or as a single drug and is also included in WHO's national list of essential medicines 2011. Due to certain physico-chemical and pharmacokinetic constraints of the drug, various approaches are undertaken to improve the half life and bioavailability of ZVD. There are novel formulation approaches such as vaginal gels, bioadhesive film, niosomes, proniosomes, nanoparticles, microparticles etc. Certain researchers have reported different designs of ZVD with other antiretroviral drugs that are used for the combination therapy in the effective treatment of HIV. This review focus on the logistics of formulation designing along with an overview of report of the various analytical techniques employed for the estimation of the ZVD in pharmaceutical dosage forms.
ACCESSION #
89900397

 

Related Articles

  • NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS.  // Complete Guide to Prescription & Nonprescription Drugs 2012;2012, p610 

    The article presents information on nucleoside reverse transcriptase inhibitors, including their dosage, usage, adverse reactions, side effects, precautions when administering, and possible interaction with other drugs.

  • Azvudine, A Novel Nucleoside Reverse Transcriptase Inhibitor Showed Good Drug Combination Features and Better Inhibition on Drug-Resistant Strains than Lamivudine In Vitro. Wang, Rui-Rui; Yang, Qing-Hua; Luo, Rong-Hua; Peng, You-Mei; Dai, Shao-Xing; Zhang, Xing-Jie; Chen, Huan; Cui, Xue-Qing; Liu, Ya-Juan; Huang, Jing-Fei; Chang, Jun-Biao; Zheng, Yong-Tang // PLoS ONE;Aug2014, Vol. 9 Issue 8, p1 

    Azvudine is a novel nucleoside reverse transcriptase inhibitor with antiviral activity on human immunodeficiency virus, hepatitis B virus and hepatitis C virus. Here we reported the in vitro activity of azvudine against HIV-1 and HIV-2 when used alone or in combination with other antiretroviral...

  • RP-HPLC Analytical Method Development And Validation For Lamivudine And Zidovudine In Pharmaceutical Dosage Forms. Shaik Karishma; Shankar Subramaniam; Meenakshi Sundaram; Muthuraman; Arvind Sivasubramanian // International Journal of PharmTech Research;Jul-Sep2013, Vol. 5 Issue 3, p1321 

    A validated RP-HPLC method for concurrent estimation of lamivudine and zidovudine in pharmaceutical dosage form has been established. The method was performed with various columns like C18 column, hypersil column, lichrosorb, and inertsil ODS column. XTerra column (150mm ×4.6 mm) was found...

  • NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS.  // Complete Guide to Prescription & Nonprescription Drugs 2012;2012, p608 

    The article presents information on non-nucleoside reverse transcriptase inhibitors, including their dosage, usage, adverse reactions, side effects, precautions when administering, and possible interaction with other drugs.

  • Positioning of HIV-protease inhibitors in clinical practice. Andreoni, M.; Perno, C. F. // European Review for Medical & Pharmacological Sciences;2012, Vol. 16 Issue 1, p10 

    The availability of more than 20 drugs for the treatment of HIV infection, and the success of the current antiretroviral regimens, should not overlook the difficulty of longterm maintaining the control of viral replication. The therapy needs to be continued for decades, if not for lifetime, and...

  • NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS.  // Complete Guide to Prescription & Nonprescription Drugs 2012;2012, p612 

    The article presents information on nucleotide reverse transcriptase inhibitors including their dosage, usage, adverse reactions, side effects, precautions when administering, and possible interaction with other drugs.

  • News from IAC.  // PharmacoEconomics & Outcomes News;9/1/2012, Issue 661, p4 

    The article features select presentations from the 2012 International AIDS Conference (IAC). A study showed that earlier initiation of antiretroviral therapy (ART) was associated with improved survival and was highly cost effective from a Ministry of Health perspective. Another study found the...

  • Severe skin rash with lamivudine in HIV infected patients:Some unusual case reports. Modak, Dolanchampa; Guha, Subhasish Kamal // Indian Journal of Pharmacology;May/Jun2013, Vol. 45 Issue 3, p298 

    Lamivudine (3TC) is a nucleoside reverse transcriptase inhibitor (NRTI) licensed for as a first line drug in Human immunodeficiency virus (HIV) infection and also in the treatment of hepatitis B. It is relatively nontoxic in nature and potentiates the antiviral effects of other NRTIs like...

  • Recent Advances in the DABOs Family as Potent HIV-1 non-Nucleoside Reverse Transcriptase Inhibitors. Mingyan Yu; Erkang Fan; Jingde Wu; Xinyong Liu // Current Medicinal Chemistry;Jun2011, Vol. 18 Issue 16, p2376 

    No abstract available.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics